References
- Gayther SA, Pharoah PD. The inherited genetics of ovarian and endometrial cancer. Curr. Opin. Genet. Dev.20, 231–238 (2010).
- Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA305, 2295–3303 (2011).
- Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol.10, 327–340 (2009).
- Menon U. Ovarian cancer screening has no effect on disease-specific mortality. Evid. Based Med. doi:10.1136/ebm.2011.100163 (2011) (Epub ahead of print).
- Skates S, Pauler D, Jacobs I. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. J. Am. Stat. Assoc.96, 429–439 (2001).
- van Nagell JR Jr, DePriest PD, Ueland FR et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer109, 1887–1896 (2007).
- Mehra K, Mehrad M, Ning G et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci. (Elite Ed.)3, 625–634 (2011).
- Brown PO, Palmer C. The preclinical natural history of serous ovarian cancer: defining the target for early detection. PLoS Med.6, e1000114 (2009).
- Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer76, 2004–2010 (1995).
- Einhorn N, Sjovall K, Knapp RC et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol.80, 14–18 (1992).
- Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ306, 1030–1034 (1993).
- Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet353, 1207–1210 (1999).
- Pepe MS, Feng Z, Janes H et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst.100, 1432–1438 (2008).